T Cell News and Research

Latest T Cell News and Research

t2c001 product obtains certificate under EMA regulations for ATMPs

t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the quality of its lead product t2c001 has been certified by the European Medicines Agency.

25 May 2010

Researchers determine critical role of bone marrow cells in fighting respiratory viruses

Researchers at Mount Sinai School of Medicine for the first time have determined that bone marrow cells play a critical role in fighting respiratory viruses, making the bone marrow a potential therapeutic target, especially in people with compromised immune systems. They have found that during infections of the respiratory tract, cells produced by the bone marrow are instructed by proteins to migrate to the lungs to help fight infection. The data are published in the current issue of Cell Host & Microbe.

25 May 2010

Researchers use zebrafish as model to analyze function of every known mutation in BBS

A research team led by scientists from the Duke University Medical Center has developed a way to simultaneously look at the effects of 125 mutations occurring on 14 different genes. They used zebrafish as a model to analyze the function of every known mutation in an inherited syndrome called BBS, Bardet-Biedl Syndrome.

25 May 2010

Excessive amounts of HSP10 inside mitochondria can halt body's ageing process: Researchers

HSP10 (Heat Shock Protein), helps monitor and organise protein interactions in the body, and responds to environmental stresses, such as exercise and infection, by increasing its production inside cells. Researchers at Liverpool, in collaboration with colleagues at the University of California, found that excessive amounts of HSP10 inside mitochondria - 'organs' that act as energy generators in cells - can halt the body's ageing process by preserving muscle strength.

25 May 2010

Biogen Idec to join global MS community to commemorate the second annual World MS Day

On May 26, Biogen Idec will join the global multiple sclerosis community to commemorate the second annual World MS Day. Biogen Idec is a leader in the fight against MS, bringing hope to the thousands of patients across the globe who benefit from the company's MS therapies and ongoing research programs.

25 May 2010

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX®) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 May 2010

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy in Washington, DC (May 17 - 22, 2010).

25 May 2010

Genzyme finalizes terms for consent decree regarding Allston manufacturing plant

Genzyme Corporation announced today that the terms for the consent decree regarding the Allston manufacturing plant have been finalized. These terms are in line with the company's expectations announced last month. The consent decree is subject to approval by the United States District Court for the District of Massachusetts.

25 May 2010

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Synta Pharmaceuticals Corp. today announced that clinical activity seen in the first stage of its trial for STA-9090 in Stage IIIB and Stage IV patients with non-small cell lung cancer, support advancing to the second stage of the trial. This result was achieved in the first pre-defined patient cohort to complete enrollment.

25 May 2010

A unique multi-modal atlas of human brain

The Allen Institute for Brain Science announced today that it has launched the Allen Human Brain Atlas, a publicly available online atlas charting genes at work throughout the human brain.

25 May 2010

Advances in health IT

The New York Times: A "broad transformation in health care underway" is "fueled in good part by technology" that "promises to shift a lot of the diagnosis, monitoring and treatment of disease from hospitals and specialized clinics, where treatment is expensive, to primary care physicians and patients themselves — at far less cost."

25 May 2010

Research work holds promise for biological substitute for dental implants

A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.

24 May 2010

Thymosin beta 4 reduces brain tissue damage, improves brain function in rats: Research paper

RegeneRx Biopharmaceuticals, Inc. announced today that in a preclinical research paper published in the May 2010 issue of the Journal of Neurosurgery, (online ahead of publication), scientists found that the systemic administration of thymosin beta 4, or Tβ4, significantly reduced brain tissue damage and improved brain function in rats with traumatic brain injury, or TBI.

24 May 2010

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.

24 May 2010

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.

24 May 2010

2010 ASCO Annual Meeting highlights new research findings on cancer

Experts from The Cancer Institute at NYU Langone Medical Center will present new research findings at the 46th Annual Meeting of The American Society of Clinical Oncology (ASCO) in Chicago, Illinois.

24 May 2010

Patent applications for Shrink's stem cell research and drug discovery tool StemDisc filed

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications for its stem cell research and drug discovery tool StemDisc have been filed.

24 May 2010

New technique designed to analyze individual immune cells may help diagnose food allergies: Study

About 30 percent of Americans believe they have food allergies. However, the actual number is far smaller, closer to 5 percent, according to a recent study commissioned by the National Institute of Allergy and Infectious Diseases. That's due in large part to the unreliability of the skin test that doctors commonly use to test for food allergies.

24 May 2010

South Dakota State University mathematicians design mathematical models to treat cancer

South Dakota State University mathematicians are helping doctors of the Mayo Clinic build mathematical models to fine-tune an innovative strategy to treat cancer.

24 May 2010

Cell Therapeutics signs agreement to sell $21.0M of shares of Series 5 Preferred Stock

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell $21.0 million of shares of its Series 5 Preferred Stock in a registered offering to three institutional investors (collectively, the "Initial Purchasers"). Each share of Series 5 Preferred Stock is convertible at the option of the holder, at any time during its existence, into 2,500 shares of common stock at a conversion price of $0.40 per share of common stock, for a total of 52,500,000 shares of common stock.

24 May 2010

T Cell News and Research

Latest T Cell News and Research

t2c001 product obtains certificate under EMA regulations for ATMPs

Researchers determine critical role of bone marrow cells in fighting respiratory viruses

Researchers use zebrafish as model to analyze function of every known mutation in BBS

Excessive amounts of HSP10 inside mitochondria can halt body's ageing process: Researchers

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

Genzyme finalizes terms for consent decree regarding Allston manufacturing plant

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

A unique multi-modal atlas of human brain

Advances in health IT

Research work holds promise for biological substitute for dental implants

Thymosin beta 4 reduces brain tissue damage, improves brain function in rats: Research paper

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

2010 ASCO Annual Meeting highlights new research findings on cancer

Patent applications for Shrink's stem cell research and drug discovery tool StemDisc filed

New technique designed to analyze individual immune cells may help diagnose food allergies: Study

South Dakota State University mathematicians design mathematical models to treat cancer

Cell Therapeutics signs agreement to sell $21.0M of shares of Series 5 Preferred Stock

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in